Gold prices edge higher; Fed indepedence fears spur safe haven buying
Matthew Pauls, a director at Soleno Therapeutics Inc. (NASDAQ:SLNO), recently sold shares worth $424,797, according to a recent SEC filing. The transaction took place on March 28, 2025, where Pauls sold 5,937 shares of common stock at a weighted average price of $71.55 per share. This sale was executed in multiple trades, with prices ranging from $71.54 to $71.69. The sale comes as SLNO trades near its 52-week high of $73.97, having delivered impressive returns of 59% year-to-date. According to InvestingPro analysis, the stock appears overvalued at current levels, with analysts setting price targets between $81 and $123.
In addition to the sale, Pauls acquired 5,937 shares through the exercise of stock options at $4.60 per share, totaling $27,310. After these transactions, Pauls holds 6,500 shares of Soleno Therapeutics directly. For investors seeking deeper insights, InvestingPro offers 14 additional investment tips and a comprehensive Pro Research Report covering this $3.3 billion market cap company. The transactions reflect ongoing changes in Pauls’ investment in the company, which specializes in electromedical and electrotherapeutic apparatus.
In other recent news, Soleno Therapeutics has received significant attention following the FDA approval of its VYKAT XR (diazoxide choline) extended-release tablets for treating hyperphagia in Prader-Willi Syndrome (PWS) patients. This approval has prompted several analyst firms to revise their price targets for Soleno. H.C. Wainwright raised its target to $100, while Stifel adjusted its target to $108, both maintaining a Buy rating. Guggenheim also increased its target to $81, citing the drug’s potential market impact. Piper Sandler maintained a $93 target, highlighting the drug’s favorable label and strategic pricing.
The approval has led to optimistic revenue projections, with Stifel estimating a potential $2 billion in revenue, an increase from its previous $1.6 billion forecast. Guggenheim’s projections align with a $1.6 billion revenue target by 2030, based on the drug’s pricing strategy. Soleno’s commercialization strategy includes deploying a sales team to target specialists treating a significant portion of the PWS patient population. Analysts believe that the drug’s market entry is well-positioned, given the high demand for PWS treatments and the drug’s minimal warnings. These developments have sparked interest among investors, with analysts expressing confidence in Soleno’s growth potential and market strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.